| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD6340 | CTRPv2 | pan-cancer | AAC | 0.086 | 0.01 |
| mRNA | tanespimycin:gemcitabine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.078 | 0.02 |
| mRNA | Cetuximab | GDSC1000 | pan-cancer | AAC | -0.079 | 0.02 |
| mRNA | neratinib | CTRPv2 | pan-cancer | AAC | -0.085 | 0.02 |
| mRNA | Methotrexate | CTRPv2 | pan-cancer | AAC | 0.089 | 0.02 |
| mRNA | paclitaxel | CTRPv2 | pan-cancer | AAC | 0.079 | 0.02 |
| mRNA | RO4929097 | CTRPv2 | pan-cancer | AAC | -0.13 | 0.02 |
| mRNA | thapsigargin | GDSC1000 | pan-cancer | AAC | 0.084 | 0.02 |
| mRNA | KW-2449 | CTRPv2 | pan-cancer | AAC | 0.072 | 0.02 |
| mRNA | FQI-1 | CTRPv2 | pan-cancer | AAC | 0.11 | 0.02 |